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ABSTRACT
Objectives: Apply ‘user testing’ methodology to test
the readability of a European Public Assessment Report
(EPAR) summary—which describes how the decision
was made by the European Medicines Agency to
approve a medicine.
Design: User testing uses mixed methods
(questionnaire and semistructured interview), applied
iteratively, to assess document performance—can
people find and understand key points of information.
Setting and participants: Testing was undertaken
with 40 members of the public in four consecutive
rounds of 10. Inclusion criteria, matched across rounds,
included range of ages and educational attainment.
Tested documents: In round 1 we tested 19 key
points of information in a printed version of the EPAR
summary for Bondronat (a cancer medicine). This was
then revised to address the findings, and tested in
round 2. In round 3 we tested the summary on-screen,
and in round 4, tested a revised on-screen version, after
addressing findings from both rounds 1 and 3.
Primary outcome measure: The target followed
European guidance for medicine leaflets: for each point
of information 90% of participants should be able to
find, and of those, 90% able to show understanding of
the point.
Results: For the original EPAR summary, 6 of the 19
points of information reached the target (both paper-
based and on-screen). After revisions to format and
content, using good practice in information writing and
design, 14 and 16 points, respectively, met the target.
The problems related to both finding (dependent on
layout, headings and design) and understanding (words
and sentences used, as well as design). We devised a
new heading structure, increased use of bullet points,
replaced difficult and technical words and divided long
sentences.
Conclusions: People had difficulty finding and
understanding key messages in the summary, but user
testing identified the problems, and application of good
practice resulted in a revised format which performed
well.
INTRODUCTION
European Public Assessment Report (EPAR)
summaries are designed to inform members
of the general public about how the
European Medicines Agency (EMA) assess
the risks and beneﬁts of a new medicine,
before deciding to grant a licence.1 They are
developed with input from patient and con-
sumer organisations, with each summary
being reviewed for readability and public-
friendly language by a relevant patient prior
to publication, but no testing of their read-
ability is undertaken with members of the
general public.
The summaries are based on the full
European Public Assessment Report, pre-
pared by the EMA for all medicines licensed
by the Agency. This full report is said to
“Reﬂect the scientiﬁc conclusion reached …
at the end of the centralised evaluation
process.” The full report is lengthy and
written for professionals. Hence, the deci-
sion to produce a summary, lay version
“written in manner understandable to the
public.”1 The EPAR summaries are available
on the EMA website, but relatively little is
known about the usefulness of these docu-
ments for members of the public, for whom
they are designed.
To test their usefulness, the performance-
based process for assessing the readability of
documents called ‘user testing’ was employed.
This method is routinely used for the manda-
tory leaﬂets for patients produced by manu-
facturers and included in every medicine
pack.2 3 The use of the same testing approach
ARTICLE SUMMARY
Strengths and limitations of this study
▪ This is the first study using a performance-based
method to assess the readability of these docu-
ments—determining whether people can find
and understand the information they need.
▪ Only one document was tested, but it is typical
of the nature of EPAR summaries, and most
improvements identified were generic and could
be applied across all such documents.
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for EPAR summaries is supported by the fact that they
have signiﬁcant similarities to patient leaﬂets.4 They are
both relatively short documents, and based on long
complex documents designed for professionals (the
Summary of Product Characteristics or SmPC in the case
of patient leaﬂets)—but revised to meet the needs of lay
people. User testing determines whether potential
readers can ﬁnd and understand key points of informa-
tion, as well as generating general feedback on the extent
to which the information meets people’s needs.5 The
process has been successfully used and reported for a
variety of health information for patients, including clin-
ical trial patient information sheets,6 medicine label
wordings7 and nationally produced medicines informa-
tion booklets.5
This work was undertaken in the wider context of
health literacy, which is not just the ability to read and
understand health information, but is now acknowl-
edged to have a wider scope. Essentially, it has three
aspects—the ability to read and understand health infor-
mation, the removal by healthcare systems of unneces-
sary complexity and barriers to patient understanding
and involvement and a wider ability to engage with the
healthcare process.8 In terms of EPAR summaries, the
three aspects relate to whether people read and under-
stand EPAR summaries, whether they contain barriers to
patient understanding (both are the focus of this study)
and do these documents enable people to better engage
in decisions about medicines (for future study).
The objective was to test, then revise and retest, an
EPAR summary (in both hard copy and on-screen
formats) using user-testing methodology to assess
whether the target audience, members of the public,
can ﬁnd and understand the key messages.
METHODS
We chose to test the EPAR summary for Bondronat, which
contains ibandronic acid, a ‘bis-phosphonate’ medicine. It
is used to treat cancers when there are high levels of
calcium in the blood, and breast cancer in particular,
when it has spread to the bone. The Bondronat summary
was chosen because the data were based on more than
one trial and its size is representative of most EPAR sum-
maries—between one and two pages long.
User testing is a process which uses mixed methods
to identify problems readers have with written informa-
tion. Good practice is then applied, designed to
address the problems identiﬁed. There are many texts
on good practice in information writing and design,
and two publications have pulled together such good
practice for people writing medicines information. First,
a UK review of medicines information for patients9
(commissioned by the Department of Health) included
an information design review, informed by ﬁve experts
in information design, which was subsequently pub-
lished in the form of key principles to guide the devel-
opment of consumer medicine information.10 Second,
the European Union (EU) guideline on readability for
package leaﬂets11 was written to ensure such informa-
tion was accessible and understandable, and is widely
used in the domain. These two complementary sources
were used to guide the revisions of the EPAR summar-
ies—each time followed by retesting to assess the effect
of the revisions made. The process has both a quantita-
tive component, using an administered questionnaire,
and a qualitative component, using a semistructured
interview, both of which generate feedback on how the
information performs—used to revise the document,
prior to retesting.3
Participants
The method used was in line with regulatory guidance
on user testing for package leaﬂets,11 12 that is, under-
taken with people from the target group for the docu-
ment—the general public. They were included if they
could speak English to native standard. They were
recruited from the database of Luto Research, the uni-
versity spin out company which undertook the user-
testing interviews. The database draws on people in the
Leeds area of the North of England, and comprises
people who have volunteered to take part in the testing
of health information materials. People were excluded if
they were current or retired healthcare professionals,
took the medicine or had the indicated condition per-
sonally (or related conditions) or were carers of such
people—as such people would have prior knowledge,
and so it would not be a fair test of the information. In
line with common practice in user testing, there were 10
participants in each round with
▸ At least three participants of each gender.
▸ Participants across the age range for the medicine.
As the medicine is used more often by middle-aged
and elderly people were recruited, at least one
person in each of the 40s, 50s, 60s and 70-plus age
groups, with no more than three people under the
age of 40.
▸ No more than two higher education graduates.
▸ At least two participants who either do not use
written documents as part of their work, or who are
currently not working or are retired.
A new set of participants was used in each round, to
prevent a learning effect. Participants were recruited in
order that age, gender, education and use of literature
(people who used written documents regularly at work
vs those who did not, were not working or were
retired) were equally matched across the four rounds of
testing.
Materials tested
EPAR summaries are available on the EMA website in
each of the ofﬁcial languages of the EU—we tested the
English version.
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Round 1
The ﬁrst document tested was the printed version of the
Bondronat EPAR summary, downloaded directly from the
EMAwebsite on 23 August 2010 (see ﬁgure 1).
Round 2
A revised hard copy version was tested, revised according
to the short-comings identiﬁed in the ﬁrst round (see
ﬁgure 2). Both documents were printed in black and
white on two single-sided A4 sheets and stapled in the
top left corner.
Round 3
The EPAR summary was shown to participants directly
on a computer screen in its original format from the
EMA website between 19 and 27 May 2011 (see
ﬁgure 3).
Round 4
After revision, subsequent to the outcome of round 3, a
revised version was tested, as a webpage mock up equiva-
lent to the original website, opened in an equivalent
Internet browser (see ﬁgure 4).
Figure 1 The original EPAR summary on paper (round 1).
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Procedure
The document was examined by two pharmacists in the
team (DKR, DB) to identify the most important points
of information in the document. There were 19 points
considered to be the most critical information (see
ﬁgure 5), under the categories:
▸ Purpose of the report and its origins (2 points);
▸ Nature of the medicine and its use (3 points);
▸ Studies that have been undertaken (5 points);
▸ Speciﬁc issues regarding the risks of Bondronat
(4 points);
▸ Decision to grant a licence (3 points);
▸ Finding more information (2 points).
A questionnaire was then designed to assess whether
people could ﬁnd and understand each key point of
information. The questions were set in the questionnaire
in an order that did not follow the sequence in the
document.
The objective of the user test in line with current
European guidance for patient leaﬂets,11 is for 90% of
participants to ﬁnd the information in the document,
and of those, 90% to be able to show that they have
understood it.
Participants were interviewed individually by one of
the three experienced trained interviewers in purpose-
built interview rooms, and guidance for interviewers in
the questionnaire ensured consistent conduct of the
interviews. Consistent scoring of the responses was
guided by ‘indicative answers’ for each question; that is,
the information from the leaﬂet that the participant was
required to provide for the answer to be scored as
understood. For example, for the question “What two
Figure 1. Continued.
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things were weighed up before the decision was made
about whether Bondronat should be approved,” the
indicative answer was “(Bondronat’s/its) beneﬁts AND
risks.”
The responses to the short semistructured interviews
were audio-recorded and transcribed verbatim. We
looked for recurring patterns of comments and selected
key quotes which illustrated these points.
The questionnaire and original EPAR summary were
pilot tested with three people from a convenience
sample to determine whether the questions worked in
practice.
Round 1 (original; paper)
The questionnaire was administered to 10 people from
the target group, interviewed individually, with each par-
ticipant ﬁrst given time to read the EPAR summary at
their own pace. Then, using the EPAR summary sup-
plied, they were asked to ﬁnd the information relevant
Figure 2 The revised EPAR summary on paper (round 2).
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to each of the 19 questions and then to explain it in
their own words (see table 1).
For each question, the interviewer noted any com-
ments or particular behaviour of the participants. At the
end of the interview, participants were asked for feed-
back about the EPAR summary.
Round 2 (revised; paper)
The original EPAR summary was then reﬁned by an
experienced health information writer (DKR), focusing
on the difﬁculties identiﬁed during the testing, and par-
ticipants’ general comments about the usefulness of the
document. These revisions were made using best prac-
tice in information writing and design (see above). This
revised EPAR summary was tested on 10 more people
from the target group for this product.
Rounds 3 and 4 (original; electronic and revised; electronic)
As EPAR summary documents are available in an electronic
format, two further rounds of testing were conducted
Figure 2. Continued.
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on-screen, to test both the original and then a revised EPAR
summary. For each version, 10 people from the target
group were interviewed, this time referring to the informa-
tion on a computer screen rather than in printed form.
Inclusion criteria for these rounds additionally included:
▸ Five people who use computers often (at least once a
day).
▸ Five people who use computers occasionally (not
every day).
We anticipated applying the learnings from the hard
copy testing to the subsequent on-screen testing.
RESULTS
Forty eligible participants were interviewed in four
rounds of 10; their characteristics in terms of gender,
age range, educational status and use of literature at
Figure 2 Continued.
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work were matched across all four rounds and are
described in table 2.
Round 1: original paper version
Quantitative findings
In the ﬁrst round of testing, with the original document
in paper format, 6 of the 19 items of information met
the target of 90% ﬁnding and 90% of those understand-
ing (see table 1).
Qualitative findings
Participants’ comments on the layout of the information
were mixed; some criticised it
Table 1 European Public Assessment Report summary paper version: original (round 1) and revised (round 2)
Questions
Original (round 1) Revised (round 2)
Number of points
found/understood
Target
met?
Number of points
found/understood
Target
met?
1 Who has this report been written for? 7 / 7 No 8 / 8 No
2 When is Bondronat used in breast cancer? 9 / 4 No 10 / 7 No
3 What is the purpose of this report? 7 / 0 No 9 / 9 Yes
4 What can the tablets do to the food pipe? 10 / 0 No 10 / 10 Yes
5 Who made the decision about Bondronat described in
this report?
10 / 1 No 9 / 9 Yes
6 What group of medicines does Bondronat belong to? 7 / 7 No 10 / 10 Yes
7 What did Committee for Medicinal Products for Human
Use (CHMP) decide about Bondronat?
10 / 10 Yes 10 / 10 Yes
8 The tablets can irritate the food pipe. Which people
cannot have the tablets as a result of this?
9 / 8 Yes 10 / 8 No
9 What two things were weighed up before decision made
about whether Bondronat should be approved?
7 / 7 No 10 / 10 Yes
10 How does Bondronat prevent fractures, or broken
bones?
10 / 9 Yes 8 / 7 No
11 In the studies looking into bone problems or
complications, what was looked at to see if Bondronat
was working?
5 / 4 No 10 / 9 Yes
12 During the studies into high calcium levels, how many
people did the 4 mg dose work in?
9 / 9 Yes 10 / 10 Yes
13 How many people receiving a Bondronat infusion got a
fever?
10 / 3 No 10 / 8 No
14 During the study of bone complications, what was
Bondronat compared with?
9 / 9 Yes 10 / 10 Yes
15 Suppose you want more information on how the
decision was made about Bondronat, what should you
do?
9 / 1 No 10 / 9 Yes
16 How many people taking the Bondronat tablet got an
inflamed food pipe?
10 / 5 No 10 / 9 Yes
17 In the research studies of high calcium levels in the
blood, what was Bondronat compared against?
9 / 9 Yes 9 / 9 Yes
18 When Bondronat was studied in the treatment of bone
complications, which group of patients got a new bone
problem first?
8 / 8 No 9 / 9 Yes
19 If you are a patient and want more information about
Bondronat, what should you do?
8 / 7 No 10 / 10 Yes
Total number of passes 6 14
Table 2 Demographics of participants in each round
Female (F) or male (M) Age range Educational status* Use of literature at work †
Round 1 (10) 7F, 3M 29–74 1=4, 2=4, 3=2 Y=3, N=7
Round 2 (10) 7F, 3M 22–71 1=4, 2=4, 3=2 Y=3, N=7
Round 3 (10) 7F, 3M 26–72 1=4, 2=4, 3=2 Y=3, n=7
Round 4 (10) 7F, 3M 21–73 1=4, 2=4, 3=2 Y=3, N=7
*Educational status: 1=education complete by 16 years; 2=A-level or equivalent; 3=higher educational graduate.
†Use of literature at work: Y=yes: uses written documents regularly at work; N=no: written document not used regularly at work, not working
or retired.
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It’s not user friendly for a start. It’s more like something
from a lecture (P1)
I found it quite difﬁcult to ﬁnd things …they weren’t
where I‘d expect them to be under the headings (P8)
One participant gave a more speciﬁc comment about
the box at the top of the page
The little box at the top with italics…people miss out
things like that, they’ll think ‘Oh it’s the boring bit’ (P3)
Others were more content with the layout:
Well set out (P 10)
Well laid out with the titles (P3)
Most participants said they did not have a problem with
the language used in the leaﬂet. Participants described
the language as ﬁne, okay and straight forward among
other things. However, one participant (P1) said it was
too technical and another said
There’s all these big words and big sentences (P5)
Revising the EPAR summary
The revision took account of the results from the ﬁrst
round of testing—both quantitative and qualitative,
where it was shown that improvements were needed.
The revision also took account of good practice in infor-
mation writing and design (see above).10
There were eight questions where, of the 10 partici-
pants, 5 or less could ﬁnd and understand the informa-
tion. Speciﬁc changes were made to address the issues
with these points of information and are described in
table 3.
As well as the changes in response to speciﬁc difﬁcul-
ties with answering the questions, other general changes
made in line with good practice in information writing
and design10 11 were
▸ Information split over two columns—some readers
struggle with long lines of text.
▸ Boxes surrounding text removed—some readers
‘read round’ boxed information.
▸ Text and headings justiﬁed to the left (‘ragged right’)
—text justiﬁed to left and right leads to unequal
gaps between words which can hinder ease of
reading.
▸ Bold text used as it is effective in giving emphasis—
replacing underlined, italicised or capitalised text
(which can make reading harder).
▸ Some paragraphs organised into bullet points—helps
to organise text for readers, and aids ﬁnding as well
as making document look more approachable.
▸ Technical or medical terms replaced with lay lan-
guage—for example, ‘hypercalcaemia’ became ‘high
calcium levels’.
Table 3 Changes made in round 1 related to the responses to specific questions
Question Changes made
2 When is Bondronat used in breast cancer? Original long sentence with multiple bracketing incorporated
into 2 new subheadings, separated into dedicated bullet points
3 What is the purpose of this report? Original text in italics in box at beginning became part of main
document under new heading ‘Who is this report for’
4 What can the tablets do to the oesophagus or food
pipe?
In original, mentioned both in the ‘How is Bondronat used’
section and ‘What is the risk’ section in isolation. Changed so
clear in both places what problem was, and how it related to
necessary actions
5 Who made the decision about Bondronat described in
this report?
Original did not make clear the membership of CHMP—
remedied in revised version under the heading ‘Who made the
decision?’ in first section of the document
11 In the studies looking into bone problems or
complications, what was looked at to see if Bondronat
was working?
Answer was number of new bone complications—in original in
middle of paragraph containing variety of pieces of information
about the study. Revision included new subheading ‘What did
the studies look for’
13 How many people receiving a Bondronat infusion got a
fever?
Original listed side effects in long paragraph with long
sentences. Revision bulleted the side effects, and separated
out those relating to ‘drip’ and tablets
15 Suppose you want more information on how the
decision was made about Bondronat, what should you
do?
Information moved from original boxed italicised text into a
new subsection titled ‘Where to get more information’
16 How many people taking the Bondronat tablet got an
inflamed food pipe?
Information became part of bulleted list of side effects (see
above), and frequency simplified from ‘seen in between 1 and
10 patients in a hundred’ to ‘affects less than 1 in 10 people’
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Importantly, the structure was revised with a focus on
making the document easier to navigate. It was split into
six main headings, section numbers were introduced
(see ﬁgure 6) and an index (‘In this leaﬂet’) was added
to aid navigation. The main headings for each of the six
sections of the leaﬂet were written as white text on a
grey band which went across the column. This clearly
demarcates the sections, helping readers to ﬁnd the
section they are looking for. Equally, the insertion of
subheadings aids navigation, such as ‘Who is this report
for’ and ‘What type of medicine is Bondronat’.
Finally, instead of separating the information from the
two types of studies (into how studied and what has
been shown), the studies of bone complications and
high calcium levels were given their own subheadings,
and became self-contained.
As a result, revisions were made to the original EPAR
summary to produce the revised version tested in round
2 (see ﬁgure 4).
Round 2: revised paper version
Quantitative findings
The objective remained that 90% of participants should
be able to ﬁnd the information in the leaﬂet and of
those 90% should be able to understand it. As can be
seen from table 1, 14 of the 19 points of information
now met this target.
Qualitative findings
Participants were generally positive about the layout of
the revised EPAR summary. Comments included it was
ﬁne how it’s laid out (P17) and it’s logical (P20). Several
Figure 3 The original EPAR summary on screen (round 3).
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participants made speciﬁc reference to the headings
and the ‘In this leaﬂet’ index as positive features of the
document, examples of comments were
I like how the headings are set out, which are set into sec-
tions which are easier to ﬁnd (P18)
It’s good the way you’ve got it laid out. ‘In this leaﬂet’
and it tells you which section’s which (P13)
It is in bullet points and its easier to read than paragraph
after paragraph of information (P14).
The language was well received and described as straight
forward (P12) and very easy to understand (P18).
Participants commented on the use of lay language, for
example, participant 15 described the language used as
everyday language.
Round 3: original electronic version
Quantitative findings
The objective that 90% of participants should be able to
ﬁnd the information in the leaﬂet and of those 90%
should be able to understand it was met for 6 of the 19
points (see table 4).
Qualitative findings
As in round 1, comments on the original EPAR
summary were mixed with regard to the layout; however,
the layout of the electronic version seemed to be better
received than the paper version. Positive comments
included it looked straight forward (P23) and It was easy to
scroll down to whichever section your question applied to (P29).
Participant 28 was more critical and suggested more care
and attention to what you present under these various
headings.
Figure 3 Continued.
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About half of the participants thought that the lan-
guage was ﬁne or okay. However, other participants were
more negative. Comments included, unnecessarily formal
and technical (P28) and it used a lot of big words (P23).
One participant anticipated the team’s revisions after
round 1 by saying Why don’t they put the easier words down
instead of the big words and then in brackets put the smaller
words (P22).
Two participants also made reference to the Package
Leaﬂet, participant 28 noted that Package Leaﬂet,
although mentioned, is not immediately available on the
website. Participant 30 also commented to say that I’m rea-
lising this is an extra leaﬂet, it would be nice to see the proper
leaﬂet because that’s probably got it a lot clearer, how to take it.
Revising the EPAR summary
The changes made after the ﬁrst round for the hard
copy version were largely replicated in the revised
on-screen version, as most of the problems identiﬁed
were similar. However, a single column format was
retained as this worked well in an on-screen format.
There were nine questions where of the 10 partici-
pants, 5 or less could ﬁnd and understand the informa-
tion. Of these, ﬁve questions (2–5 and 15) were
addressed, as a result of problems with the hard copy
original. This left four additional points to address,
which are described in table 5.
Round 4: revised electronic version
Quantitative findings
The objective that 90% of participants should be able to
ﬁnd the information in the leaﬂet and of those 90%
should be able to understand it was met for 16 of the 19
points of information (see table 4).
Qualitative findings
The layout was generally well received by participants in
this round. It was described as nice and clear (P31) and
Table 4 European Public Assessment Report summary screen versions: original (round 3) and revised (round 4)
Questions
Original (round 3) Revised (round 4)
Number of points
found /understood
Target
met?
Number found/
understood
Target
met?
1 Who has this report been written for? 4 / 0 No 10 / 9 Yes
2 When is Bondronat used in breast cancer? 9 / 1 No 10 / 9 Yes
3 What is the purpose of this report? 6 / 0 No 9 / 9 Yes
4 What can the tablets do to the food pipe? 10 / 0 No 10 / 10 Yes
5 Who made the decision about Bondronat described in this
report?
9 / 0 No 10 / 9 Yes
6 What group of medicines does Bondronat belong to? 5 / 5 No 10 / 10 Yes
7 What did the Committee for Medicinal Products for
Human Use (CHMP) decide about Bondronat?
9 / 8 Yes 10 / 9 Yes
8 The tablets can irritate the food pipe. Which people
cannot have the tablets as a result of this?
10 / 9 Yes 9 / 8 Yes
9 What two things were weighed up before the decision was
made about whether Bondronat should be approved?
3 / 3 No 10 / 10 Yes
10 How does Bondronat prevent fractures, or broken bones? 10 / 9 Yes 7 / 6 No
11 In the studies looking into bone problems or
complications, what was looked at to see if Bondronat
was working?
8 / 8 No 7 / 7 No
12 During the studies into high calcium levels, how many
people did the 4 mg dose work in?
7 / 7 No 10 / 9 Yes
13 How many people receiving a Bondronat infusion got a
fever?
10 / 9 Yes 10 / 9 Yes
14 During the study of bone complications, what was
Bondronat compared with?
10 / 8 No 10 / 10 Yes
15 Suppose you want more information on how the decision
was made about Bondronat, what should you do?
7 / 2 No 10 / 9 Yes
16 How many people taking the Bondronat tablet got an
inflamed food pipe?
9 / 8 Yes 10 / 10 Yes
17 In the research studies of high calcium levels in the blood,
what was Bondronat compared against?
7 / 7 No 9 / 9 Yes
18 When Bondronat was studied in the treatment of bone
complications, which group of patients got a new bone
problem first?
6 / 5 No 8 / 5 No
19 If you are a patient and want more information about
Bondronat, what should you do?
9 / 9 Yes 10 / 10 Yes
Total number of passes 6 16
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simple (P32). Participant 40 also mentioned the different
sections of the leaﬂet and said that it was well structured
and in different categories which all make sense.
In general, comments received about the language
were positive. It was described as easy to understand (P31),
and not complicated (P39).
There were varying views on the electronic presenta-
tion. Participant 32 said I love being able to do it on the
screen. Whereas another participant thought that there is
a lot of scrolling through the screen (P40). Other comments
included
It wouldn’t be very much use to me reading it on a com-
puter because I haven’t got a computer (P34)
Qualitative feedback on EPAR summaries in general
Participants from all four rounds of testing were asked
to provide feedback in terms of their opinions on EPAR
summaries in general.
The majority (32/40) of the participants interviewed
thought that the information in the EPAR summary
report would be useful.
If they could ﬁght their way through it, it would be quite
useful (P3)
It was good how they gave the background … explain the
beneﬁts … so people can see a reason for taking the
drug (P33)
Figure 4 The revised EPAR summary on screen (round 4).
Table 5 Changes made in round 3 related to the responses to specific questions
Questions Changes made
1 Who has this report been written for? Dedicated subheading ‘Who is this report for” introduced
6 What group of medicines does Bondronat belong to? This information, formerly in the section ‘How does
Bondronat work’ repositioned in the new subsection ‘What
type of medicine is Bondronat’?
9 What two things were weighed up before the decision was
made about whether Bondronat should be approved?
Information bulleted in revised version, to aid finding and
understanding
18 When Bondronat was studied in the treatment of bone
complications, which group of patients got a new bone
problem first?
Simplified through new subheading of ‘What did the studies
show?’
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I think it’s good to know that somebody in authority has
checked it out (P20)
Those who did not think it would be useful made
comments about the complexity of the information.
When asked whether people who were not patients
would ﬁnd it useful, the most common response was
that carers or people who know someone with the indi-
cated conditions might ﬁnd it useful to read the
document. A few participants listed some groups of
people who might utilise the information, for example,
healthcare professionals (n=4) and researchers (n=2).
DISCUSSION
The principal ﬁnding of this research is that the current
EPAR summary format could be improved, with only 6
of the 19 items of information found and understood
(to the level required for package leaﬂets) for both the
paper-based and screen formats. However, the revised
format, guided by user testing with the target popula-
tion, better met people’s needs, where 14 and 16 points,
respectively, met the target.
Figure 4 Continued.
Figure 4 Continued.
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As with most documents that are user tested, there were
problems related to both ﬁnding information and under-
standing the information. Importantly, the heading
structure did not work well, and points of information
need to be placed where lay people would expect to ﬁnd
them (rather than where professionals are used to placing
them). The addition of new numbered headings and sub-
headings (along with the inclusion of an ‘In this leaﬂet’
listing near the beginning) led to improvements in per-
formance. Important points relating to the content were
the need to clarify the purpose of the document at the
beginning: saying what it is, and who it is for. The key
recommendations are described in box 1.
A previous study of EPAR Summaries in Denmark by
Askehave and Zethsen4 focused on their nature as a
‘mandatory genre’. The study involved a questionnaire
on lay respondents’ opinion of the text, alongside an
exercise in which participants marked problem words,
sentences or paragraphs in the document. The authors
concluded that most participants did not think the sum-
maries fulﬁl their purpose of providing information
which is understandable and useful to lay persons. Our
ﬁndings with a UK population concur with those in
Denmark, and the addition of a performance-based
testing method also pointed the way to improvements.
LIMITATIONS
The study was based on one EPAR summary, which was
of a representative size for such summaries. However, an
EPAR summary for a medicine for cancer may be sub-
stantially different from one on a medicine for epilepsy
or schizophrenia in terms of what the public need to
know. This work would be enhanced by similar studies
Figure 5 Key points of information tested.
Figure 6 Original and revised heading and subheading
structure.
Box 1 Recommendations
General information design
▸ Appropriate use of bullets, no italics or boxes.
▸ Two columns for paper version.
▸ Clear signposting with main headings (numbered) and sub-
headings which work for lay people (see headings structure in
figure 2).
▸ Still a need for both hard copy and on-screen versions. The
printable version from the website needs to be designed to
work well on paper—not just replicate what is on the screen.
Key messages
▸ Clarify the purpose of the document up front: what it is and
who it is for.
▸ Keep the information about each study (or set of studies)
together, that is, do not separate out ‘How has been studied’
and ‘What benefit has been shown in studies’.
▸ The general public may not be the right audience? It may be
more usefully aimed at people who are take or are considering
taking the medicine concerned and people from relevant
patient groups, rather than the general public.
Future developments
▸ Clarify relationship with Package Leaflet—presenting both
together would allow removal of most of the duplicated infor-
mation, and allow the European Public Assessment Report
summary to focus on the studies, their findings and the
decision-making process.
Raynor DK, Bryant D. BMJ Open 2013;3:e003185. doi:10.1136/bmjopen-2013-003185 15
Open Access
on different types of medicine. However, in the mean-
time, most of the improvements identiﬁed were generic,
and not speciﬁc to the type of medicine, and would be
applicable to most summaries.
We refer later in this section to studies which show that
patients want more balanced information, including
beneﬁt information. However, we did not include such a
heading in the ﬁnal version of the EPAR summary, for
example, ‘What are the beneﬁts of Bondronat?’ The inclu-
sion of such a heading may need to be studied in future
research on these documents.
Relationship with wider literature
Previous studies examining health literacy have also
found that many people have difﬁculty in understanding
health information in the UK,13 Australia14 and the
USA,15 including statutory medicines information.16
Furthermore, a review of drug information for consumers
and patients with a focus on the EU concluded that ‘drug
authorities’ should see themselves more as a source of
medicine information for patients.17 This study has also
demonstrated the concept that unnecessary complexity
can act as a barrier to patient understanding2—shown
here in the fact that a minority of the items of informa-
tion could be found and understood. What this work
does not show is whether the revised summaries enable a
wider ability to become more empowered to engage with
the healthcare process—part of the wider nature of
health literacy18—this needs further study.
What is the target group?
Most stakeholders would agree that people should be
able to ﬁnd out how the decision to license a medicine
was made. However, the full EPAR is never going to be a
document which is going to be useful to lay people, and
EPAR summaries are a laudable attempt to open up the
medicines licensing process in the EU. Although the
intention was that they should be understandable to the
public, their effectiveness has not been previously tested.
Owing to the target group, as stated by the EMA, being
‘the public’, the participants in this series of tests were
representative of the general population, weighted to
more older people and including people of lower educa-
tional attainment. However, one ﬁnding of the study is
that it was not certain for some participants as to
whether this type of information would be useful to
them personally. Although not stated by participants, it
could be argued that the target group should be people
with the condition for which the medicine is used, who
are actively involved in their healthcare, and people
from relevant patient groups (rather than members of
the public generally). If so, then future testing should
be undertaken with people from these target groups.
Relationship with package leaflet
Some participants raised the question of the relationship
between the EPAR summary and the Package Leaﬂet. It
is clear that there is considerable overlap between the two
documents. The EPAR summary has general information,
also contained in the leaﬂet (about what the drug is,
what it is used for and how it is used, along with some
side effects). The rest of the document, detailing the
studies and the decision process would not make sense
without that background information. However, the back-
ground information does appear to be problematic, and
takes the focus away from the key points relating to the
research studies and the decision process. One option
would be to incorporate the patient leaﬂet (or parts of it)
into an EPAR summary ‘package’. This could comprise
an introduction, which describes the purpose of the
‘package’, and explain that the reader should ﬁrst read
the leaﬂet, and then the EPAR summary. The latter could
then focus only on the studies and the decision-making
process, that is, the information under the current head-
ings ‘How Bondronat was studied’ and ‘Why Bondronat
was approved’.
A notable difference between the EPAR summary and
the package leaﬂet is that the former explicitly mentions
the likelihood of beneﬁt. This is generally not present in
patient leaﬂets, certainly not with any numerical infor-
mation about the beneﬁt. However, there is increasing
support to include more beneﬁt information in package
leaﬂets,19 to answer the call from patients that they want
more balanced information on which they can make
decisions about whether a medicine is right for them.20
At present, including this information is a problem,
because of the current requirement that the leaﬂet is
based on the SmPC. A second problem is that the infor-
mation needs to be presented in a way that is under-
standable to the public. It could be argued that
including beneﬁt information based on the EPAR
summary (in the revised format developed in this study)
would solve both problems.
This study is further evidence to support the applic-
ability and usability of the user-testing method to
improve a variety of health-related information. It also
shows that paper-based EPAR summaries as well as
on-screen versions continue to be needed by different
groups of the population. Importantly, the information
needs to be appropriately formatted for each medium—
as used in this study.
Finally, this study has shown that there is support for
the idea of a document which describes in patient
friendly terms, the studies on which the decision was
made to make the medicine available in the EU.
However, the EPAR summary document did not
perform well in user testing, but the testing highlighted
the problems, and application of good practice resulted
in revised formats which performed well.
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